Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;19(1):19-27.
doi: 10.1016/j.jsps.2010.11.002. Epub 2010 Nov 4.

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Walid Sakr  1 , Fars Alanazi, Adel Sakr
Affiliations

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets

Walid Sakr et al. Saudi Pharm J. 2011 Jan.

Abstract

The objective of this study was to evaluate Kollidon SR for the development of extended release Albuterol Sulphate matrix tablets in comparison with other polymers as Hydroxypropylmethylcellulose K15M, Carbopol 71G NF, and Eudragit L100-55. The mechanical properties of the tablets were improved as concentration of Kollidon SR or other polymers increased. It was found that Kollidon SR 30% (w/w) and HPMC 30% (w/w) tablets have f 2 similarity factor of 83.5 in their Albuterol Sulphate dissolution profile. The marketed product was found to release 99.7% of drug content within 8 h, while Kollidon SR and HPMC tablets with 30% (w/w) polymer concentration level released 92.7% and 92.9% respectively of drug content within 8 h. Kollidon SR has a unique character of maintaining tablets geometric shape until the end of dissolution test, this is mainly due to the water insoluble content, polyvinyl acetate, forming 80% (w/w) of Kollidon SR, while the remaining content 20% (w/w) is the water soluble, polyvinylpyrrolidone, responsible for pore formation causing a diffusion controlled release. Drug release from all previous formulations is best described to be controlled by more than one kinetic mechanism of release. In conclusion, Kollidon SR and HPMC and Carbopol were found to be potential candidates for the development of extended release of Albuterol Sulphate tablets.

Keywords: Albuterol Sulphate; Extended release; Kollidon SR; Matrix tablets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Albuterol Sulphate tablets dissolution curves (mean + SD, n = 6), with different polymers at ratios 10–30% (w/w): (A) Carbopol 71G NF tablets, (B) Eudragit L100-55 tablets, (C) HPMC K15M tablets and (D) Kollidon SR tablets.
Figure 2
Figure 2
Swelling behavior of different tablets in water at different time intervals: (A) Carbopol 30% tablets, (B) Eudragit 30% tablets, (C) HPMC 30% tablets, (D) Kollidon 30% tablets and (E) Marketed product.
Figure 3
Figure 3
Comparison of tablets dissolution at 30% polymer concentration results indicated as; (mean + SD, n = 6).
Figure 4
Figure 4
Albuterol Sulphate tablets hardness and friability tests results indicated as; (mean + SD, n = 6), with different polymers at ratios 10–30% (w/w): (A) Carbopol 71G NF tablets, (B) Eudragit L100-55 tablets, (C) HPMC K15M tablets and (D) Kollidon SR tablets.
Figure 5
Figure 5
Time required for 50% drug release at 30% polymer concentration.
See this image and copyright information in PMC

References

    1. Colombo P., Conte U., Gazzaniga A., Maggi L., Sangalli M., Peppas N., Manna A. Drug release modulation by physical restrictions of matrix swelling. Int. J. Pharm. 1990;63:43–48.
    1. Colombo P., Bettini R., Santi P., Peppas N. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. PSTT. 2000;3:198–204. - PubMed
    1. Corti G., Cirri M., Maestrelli F., Mennini N., Mura P. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-b-cyclodextrin. Eur. J. Pharm. Biopharm. 2008;68:303–309. - PubMed
    1. Claxton A., Cramer J., Pierce C. Asystematic review of the associations between dose regimens and medications compliance. Clin. Ther. 2001;23:1296–1310. - PubMed
    1. Draganoiu E., Andheria M., Sakr A. Evaluation of the new polyvinylacetate/povidone excipient for matrix sustained release dosage forms. J. Pharm. Ind. 2001;63:624–629.